[Pure red cell aplasia developed during treatment with erythropoietin. Complete remission during immunosuppressive therapy].
In a patient with chronic renal failure due to diabetes mellitus pure red-cell aplasia developed during treatment with erythropoietin (epoetin alfa). The treatment with erythropoietin was stopped and immunosuppressive therapy resulted in normalisation of the bone marrow function and increase of the Hb level to normal values. Pure red cell aplasia which develops during treatment with erythropoietin has recently been reported in a few other patients with anaemia due to chronic renal failure. Hitherto our patient is the first case reported in Denmark.
Høi-Hansen
Thomas
T
Medicinsk Afdeling F, Hillerød Sygehus, DK-3400 Hillerød. peboha@fa.dk
Lauritzen
Anne M Falensteen
AM
Hansen
Per Boye
PB
D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects*; D006397:Hematinics / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced*; D012075:Remission, Spontaneous
D006397:Hematinics; D007166:Immunosuppressive Agents; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa